Whitehawk Therapeutics (WHWK)
NASDAQ:WHWK
Top Page
Whitehawk Therapeutics
(NASDAQ:WHWK)
Select Model
Select Model
Rating:51Neutral
Price Target:
$3.00
▼(-5.06% Downside)
Action:ReiteratedDate:03/24/26
The score is primarily held back by weak financial performance—large ongoing losses, a sharp revenue decline, and significant cash burn—despite a low-debt balance sheet and improved gross margin. Technicals are moderately supportive with price above major moving averages and positive MACD, but valuation remains difficult to justify on earnings given the negative P/E and no indicated dividend.
Positive Factors
Low leverage / no debt
A zero-debt balance sheet materially reduces refinancing and interest-rate risk and preserves strategic optionality. Over the next 2–6 months this capital structure gives management flexibility to fund clinical or commercial programs, negotiate financings from a position of strength, and avoid forced deleveraging.
Negative Factors
Sharp revenue decline
A ~50% YoY revenue decline is a durable structural concern: it weakens scale economics, impairs absorption of fixed costs, and raises questions about demand or product execution. Without a clear revenue recovery plan, margin improvements may not translate into sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / no debt
A zero-debt balance sheet materially reduces refinancing and interest-rate risk and preserves strategic optionality. Over the next 2–6 months this capital structure gives management flexibility to fund clinical or commercial programs, negotiate financings from a position of strength, and avoid forced deleveraging.
Read all positive factors
Whitehawk Therapeutics (WHWK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$149.14M
Dividend YieldN/A
Average Volume (3M)3.35M
Price to Earnings (P/E)―
Beta (1Y)0.81
Revenue Growth-42.62%
EPS GrowthN/A
CountryUS
Employees40
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding47,196,564
10 Day Avg. Volume9,835,549
30 Day Avg. Volume3,352,856
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue15.62
Enterprise Value/Gross Profit17.49
Enterprise Value/Ebitda-1.01
Forecast
1Y Price Target
$6.50Price Target Upside105.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.24
Revenue Forecast (FY)N/A
Whitehawk Therapeutics Business Overview & Revenue Model
Company Description
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers....
Whitehawk Therapeutics Earnings Call Summary
Earnings Call Date:Mar 18, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with significant strategic transformations, a promising pipeline of ADC therapies, and strong financial positioning. However, there are concerns about increased R&D expenses and net losses, which are common in early biotech transitions.Positive Updates
Transformation and Strategic Transactions
Whitehawk Therapeutics was launched from Aadi Biosciences, including in-licensing 3 ADCs from Wuxi Biologics, divestiture of FYARRO to Kaken Pharmaceuticals, and $100 million pipe financing, approved by stockholders.
Negative Updates
Increased R&D Expenses
Research and development expenses for Q4 increased to $14.3 million compared to $12.8 million in the prior year quarter, primarily due to in-process R&D expenses related to the acquired ADC programs.
Read all updates
Q4-2024 Updates
Positive
Negative
Transformation and Strategic Transactions
Whitehawk Therapeutics was launched from Aadi Biosciences, including in-licensing 3 ADCs from Wuxi Biologics, divestiture of FYARRO to Kaken Pharmaceuticals, and $100 million pipe financing, approved by stockholders.
Read all positive updates
Company Guidance
In the earnings call for the fourth quarter and full year 2024, Whitehawk Therapeutics provided guidance on their transformative shift from Aadi Biosciences to an ADC-focused company. The key metrics highlighted include a $100 million PIPE financing and the divestiture of FYARRO, which resulted in a financial position of $170 million to $180 million in cash and equivalents, expected to fund operations into 2028. The company reported FYARRO net product sales of $7.2 million for the fourth quarter, marking a 14% increase from the previous year, and $26 million for the full year, a 7% rise from 2023. Research and development expenses increased to $14.3 million for the quarter and $51 million for the year, primarily due to ADC program acquisitions. Whitehawk plans to file three Investigational New Drug (IND) applications within 15 months for their ADC candidates, targeting PTK7, MUC16, and SEZ6, with anticipated Phase 1 trials in several high-potential cancer indications.Whitehawk Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.14M | 25.98M | 24.35M | 15.22M | 1.12M |
| Gross Profit | 6.38M | -28.07M | -27.38M | -18.78M | -18.55M |
| EBITDA | -114.40M | -64.63M | -71.76M | -58.80M | -36.96M |
| Net Income | -20.60M | -63.69M | -65.77M | -60.51M | -110.09M |
Balance Sheet | |||||
| Total Assets | 150.83M | 70.32M | 132.42M | 184.24M | 157.91M |
| Cash, Cash Equivalents and Short-Term Investments | 145.70M | 47.24M | 108.84M | 172.56M | 148.99M |
| Total Debt | 0.00 | 833.00K | 1.27M | 1.66M | 605.00K |
| Total Liabilities | 14.52M | 17.84M | 27.23M | 25.86M | 21.50M |
| Stockholders Equity | 136.31M | 52.48M | 105.19M | 158.38M | 136.41M |
Cash Flow | |||||
| Free Cash Flow | -97.98M | -61.20M | -63.63M | -50.08M | -22.47M |
| Operating Cash Flow | -97.43M | -59.55M | -59.66M | -49.64M | -22.42M |
| Investing Cash Flow | 11.89M | 25.20M | 83.21M | -132.89M | 25.15M |
| Financing Cash Flow | 94.38M | 130.00K | 326.00K | 72.62M | 141.80M |
Whitehawk Therapeutics Technical Analysis
Neutral
3.16
Price Trends
3.21
Negative
2.80
Positive
2.37
Positive
Market Momentum
0.08
Positive
38.21
Neutral
18.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WHWK, the sentiment is Neutral. The current price of 3.16 is below the 20-day moving average (MA) of 3.67, below the 50-day MA of 3.21, and above the 200-day MA of 2.37, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 38.21 is Neutral, neither overbought nor oversold. The STOCH value of 18.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for WHWK.
Whitehawk Therapeutics Risk Analysis
Whitehawk Therapeutics disclosed 101 risk factors in its most recent earnings report. Whitehawk Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Whitehawk Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $133.88M | 1.57 | 25.12% | ― | ― | 814.20% | |
55 Neutral | $237.97M | -2.59 | -47.04% | ― | ― | 69.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $149.14M | -7.27 | -10.35% | ― | -42.62% | ― | |
47 Neutral | $86.49M | -1.71 | -305.39% | ― | -90.18% | -17.93% | |
43 Neutral | $186.22M | -1.36 | -120.20% | ― | -9.70% | 23.23% |
* Healthcare Sector Average
WHWK
Whitehawk Therapeutics
3.16
1.38
77.53%
MGNX
MacroGenics
2.93
1.66
130.71%
ORMP
Oramed Pharm
3.31
1.32
65.91%
SPRB
Spruce Biosciences
63.04
41.28
189.71%
CNTX
Context Therapeutics
2.59
1.98
323.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.